Taika Capital LP Takes $771,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Taika Capital LP bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 35,000 shares of the company’s stock, valued at approximately $771,000.

A number of other institutional investors have also recently modified their holdings of the business. Sowell Financial Services LLC grew its position in shares of Teva Pharmaceutical Industries by 23.0% during the 4th quarter. Sowell Financial Services LLC now owns 49,600 shares of the company’s stock valued at $1,093,000 after acquiring an additional 9,291 shares during the period. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $450,000. Callan Family Office LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $207,000. Raymond James Financial Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $38,914,000. Finally, Assetmark Inc. grew its position in shares of Teva Pharmaceutical Industries by 1,370.3% in the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock valued at $115,000 after purchasing an additional 4,851 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.55% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TEVA has been the topic of several research analyst reports. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $15.34 on Monday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The firm has a market capitalization of $17.40 billion, a P/E ratio of -10.58, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The stock’s fifty day moving average is $18.85 and its two-hundred day moving average is $18.38. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.